JP2008508858A - マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 - Google Patents

マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 Download PDF

Info

Publication number
JP2008508858A
JP2008508858A JP2007513435A JP2007513435A JP2008508858A JP 2008508858 A JP2008508858 A JP 2008508858A JP 2007513435 A JP2007513435 A JP 2007513435A JP 2007513435 A JP2007513435 A JP 2007513435A JP 2008508858 A JP2008508858 A JP 2008508858A
Authority
JP
Japan
Prior art keywords
antibody
seq
ron
fragment
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007513435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508858A5 (https=
Inventor
ペレイラ，ダニエル
ルー，ダン
Original Assignee
イムクローン システムズ インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イムクローン システムズ インコーポレイティド filed Critical イムクローン システムズ インコーポレイティド
Publication of JP2008508858A publication Critical patent/JP2008508858A/ja
Publication of JP2008508858A5 publication Critical patent/JP2008508858A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007513435A 2004-05-13 2005-05-13 マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 Pending JP2008508858A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57164804P 2004-05-13 2004-05-13
PCT/US2005/016920 WO2005120557A2 (en) 2004-05-13 2005-05-13 Inhibition of macrophage-stimulating protein receptor (ron)

Publications (2)

Publication Number Publication Date
JP2008508858A true JP2008508858A (ja) 2008-03-27
JP2008508858A5 JP2008508858A5 (https=) 2008-07-03

Family

ID=35503660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007513435A Pending JP2008508858A (ja) 2004-05-13 2005-05-13 マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害

Country Status (5)

Country Link
US (1) US20090246205A1 (https=)
EP (1) EP1773881A4 (https=)
JP (1) JP2008508858A (https=)
CA (1) CA2566647A1 (https=)
WO (1) WO2005120557A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012517223A (ja) * 2009-02-10 2012-08-02 第一三共株式会社 抗ｍｓｔ１ｒ抗体およびそれらの使用
JP2013515508A (ja) * 2009-12-29 2013-05-09 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｒｏｎ結合構築体およびその使用方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029807A1 (fr) * 2006-09-06 2008-03-13 Japan Science And Technology Agency Nouveau polypeptide ayant une cytotoxicité contre le cancer, procédé pour cribler le polypeptide et utilisation du polypeptide
US20100239590A1 (en) * 2007-06-20 2010-09-23 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
CL2008003449A1 (es) * 2007-11-21 2010-02-19 Imclone Llc Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer.
AU2008340011A1 (en) * 2007-12-21 2009-07-02 Patrys Limited PM-2 antibodies and methods for treating metastasis
JP2011509687A (ja) * 2008-01-22 2011-03-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｒｏｎ抗体およびその使用
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2010014751A2 (en) * 2008-07-29 2010-02-04 Texas Tech University Monoclonal antibody zt/2f2 in targeted therapy of cancers overexpressing the ron receptor tyrosine kinase
AR076508A1 (es) * 2009-05-01 2011-06-15 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AR082194A1 (es) 2010-07-06 2012-11-21 Aveo Pharmaceuticals Inc Anticuerpos anti-ron
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
WO2013173745A1 (en) * 2012-05-18 2013-11-21 Galaxy Biotech, Llc Monoclonal antibodies to macrophage stimulating protein
TW202037609A (zh) 2012-11-01 2020-10-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
JP6488520B2 (ja) * 2013-08-20 2019-03-27 国立研究開発法人科学技術振興機構 ヒト抗体κ型軽鎖複合体含有組成物及びその製造方法
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN110799211B (zh) 2016-09-08 2024-11-22 美国德州精准药靶有限公司 特异性识别丛蛋白-信号素-整合素结构域的抗ron单克隆抗体的药物呈递作用及其在肿瘤治疗中的应用
AU2019205279A1 (en) * 2018-01-08 2020-07-30 Susavion Biosciences, Inc. Compositions and methods of treating cancer with glycomimetic peptides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5861301A (en) * 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
CA2409991A1 (en) * 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
US7235523B2 (en) * 2001-04-13 2007-06-26 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
CA2450793A1 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
AU2003216341A1 (en) * 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
US20040101920A1 (en) * 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US20040185506A1 (en) * 2003-03-21 2004-09-23 Heavner George A. Epitope mapping using nuclear magnetic resonance

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012517223A (ja) * 2009-02-10 2012-08-02 第一三共株式会社 抗ｍｓｔ１ｒ抗体およびそれらの使用
US9403909B2 (en) 2009-02-10 2016-08-02 Daiichi Sankyo Company, Limited Anti-MST1R antibodies and uses thereof
JP2013515508A (ja) * 2009-12-29 2013-05-09 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｒｏｎ結合構築体およびその使用方法

Also Published As

Publication number Publication date
WO2005120557A3 (en) 2006-05-26
EP1773881A2 (en) 2007-04-18
CA2566647A1 (en) 2005-12-22
WO2005120557A2 (en) 2005-12-22
EP1773881A4 (en) 2008-08-06
US20090246205A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
JP7301106B2 (ja) 線維芽増殖因子受容体２に対するモノクローナル抗体
JP5324593B2 (ja) マクロファージ刺激タンパク質受容体（ｒｏｎ）の阻害およびその処置の方法
EP1735348B1 (en) Human anti-epidermal growth factor receptor antibody
US7740850B2 (en) PDGFRβ-specific antibodies
JP2008508858A (ja) マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害
US8143025B2 (en) Antibodies against vascular endothelial growth factor receptor-1
CN101612399B (zh) 用作治疗继发性骨肿瘤的抗PDGFRα抗体
TWI381848B (zh) 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
EP3685855B1 (en) Human anti-vegfr-2/kdr antibodies
US20220017617A1 (en) Efficiently expressed egfr and pd-l1 bispecific binding proteins
CN101233155B (zh) 人抗表皮生长因子受体抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080512

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090624

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111025